Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

991
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
991
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

562
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient sensitization profile and fish species' tolerance in children with IgE-mediated fish allergy.

Allergologia et immunopathologia·2026
Same author

Panallergen sensitization in children with eosinophilic esophagitis: a pilot study.

Frontiers in allergy·2026
Same author

Recent developments in nanotechnology-enhanced immunotherapy for glioblastoma.

Immunotherapy·2026
Same author

The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.

The Journal of clinical endocrinology and metabolism·2026
Same author

A Randomized Study of the <i>Glunovo</i> Real-time CGM Effectiveness in Individuals With Poorly Controlled Type 2 Diabetes.

Journal of the Endocrine Society·2026
Same author

Identifying Predictors for the Acquisition of Tolerance to Cow's Milk Protein in Infants with Food Protein-Induced Allergic Proctocolitis (FPIAP): Multifactorial Analysis of Two Italian Cohorts.

Nutrients·2026

Related Experiment Video

Updated: Mar 6, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.5K

Immunotherapy for type 1 diabetes.

Davide Frumento1, Moufida Ben Nasr2,3, Basset El Essawy4

  • 1DITID, San Raffaele Hospital, Milan, Italy.

Journal of Endocrinological Investigation
|March 6, 2017
PubMed
Summary

Type 1 diabetes (T1D) remains challenging to treat, with many approaches failing. Stem cell therapies show promise for reversing T1D, offering hope for patients.

Keywords:
ClinicalImmunotherapyTrialsType 1 diabetes

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 6, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.5K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.4K

Area of Science:

  • Immunology
  • Endocrinology
  • Regenerative Medicine

Background:

  • Type 1 diabetes (T1D) results from pancreatic beta-cell destruction, leading to insulin dependence.
  • Current medical research has struggled to halt T1D onset or reverse existing disease.
  • Existing treatments primarily manage symptoms rather than addressing the underlying autoimmune cause.

Purpose of the Study:

  • To critically review the current state of immunotherapy for T1D.
  • To highlight key clinical achievements and challenges in T1D immunotherapy.
  • To identify promising therapeutic avenues for T1D treatment.

Main Methods:

  • Focus on clinical immunotherapy research, excluding extensive preclinical animal studies.
  • Critical analysis of published clinical trial data and therapeutic outcomes.
  • Evaluation of immunomodulatory strategies and cell-based therapies.

Main Results:

  • Stem cell therapies have demonstrated the most promising clinical results to date for T1D.
  • Immune ablation and conventional immunosuppressants have largely failed to meet preclinical expectations.
  • Significant discrepancies exist between preclinical findings and clinical efficacy in T1D immunotherapy.

Conclusions:

  • Stem cell therapy represents a leading strategy for T1D treatment.
  • Further development is needed to translate promising preclinical findings into effective clinical therapies.
  • The ultimate goal is to develop safe and feasible clinical approaches for a T1D cure.